ES2530866T3 - Marcador temprano de proteinuria en pacientes tratados con un tratamiento anti-VEGF - Google Patents

Marcador temprano de proteinuria en pacientes tratados con un tratamiento anti-VEGF Download PDF

Info

Publication number
ES2530866T3
ES2530866T3 ES10842718T ES10842718T ES2530866T3 ES 2530866 T3 ES2530866 T3 ES 2530866T3 ES 10842718 T ES10842718 T ES 10842718T ES 10842718 T ES10842718 T ES 10842718T ES 2530866 T3 ES2530866 T3 ES 2530866T3
Authority
ES
Spain
Prior art keywords
proteinuria
patients treated
vegf treatment
early marker
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10842718T
Other languages
English (en)
Inventor
Vesna D Garovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Original Assignee
Mayo Foundation for Medical Education and Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research filed Critical Mayo Foundation for Medical Education and Research
Application granted granted Critical
Publication of ES2530866T3 publication Critical patent/ES2530866T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Método para evaluar a un ser humano que ha recibido una terapia anti-VEGF para detectar un riesgo de desarrollar proteinuria, comprendiendo dicho método: determinar si una muestra de orina de un ser humano que recibe terapia anti-VEGF contiene o no uno o más podocitos urinarios o evidencia de uno o más podocitos urinarios; en el que la presencia de dicho uno o más podocitos urinarios o dicha evidencia indica que dicho ser humano corre el riesgo de desarrollar proteinuria.
ES10842718T 2009-12-21 2010-12-21 Marcador temprano de proteinuria en pacientes tratados con un tratamiento anti-VEGF Active ES2530866T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28851409P 2009-12-21 2009-12-21
PCT/US2010/061543 WO2011084791A2 (en) 2009-12-21 2010-12-21 Early marker of proteinuria in patients treated with an anti-vegf treatment

Publications (1)

Publication Number Publication Date
ES2530866T3 true ES2530866T3 (es) 2015-03-06

Family

ID=44306097

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10842718T Active ES2530866T3 (es) 2009-12-21 2010-12-21 Marcador temprano de proteinuria en pacientes tratados con un tratamiento anti-VEGF

Country Status (8)

Country Link
US (4) US20130034861A1 (es)
EP (1) EP2517014B1 (es)
JP (1) JP5753541B2 (es)
AU (1) AU2010339723B2 (es)
BR (1) BR112012017767A2 (es)
CA (1) CA2785273A1 (es)
ES (1) ES2530866T3 (es)
WO (1) WO2011084791A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090104649A1 (en) 2007-06-11 2009-04-23 Garovic Vesna D Markers for preeclampsia
US20130034861A1 (en) 2009-12-21 2013-02-07 Mayo Foundation For Medical Education And Research Early marker of proteinuria in patients treated with an anti-vegf treatment
WO2014104019A1 (ja) * 2012-12-26 2014-07-03 デンカ生研株式会社 尿中ポドサイトの検出方法
WO2021055089A1 (en) * 2019-09-20 2021-03-25 The University Of North Carolina At Chapel Hill Methods of identifying risk of bevacizumab-induced proteinuria and hypertension

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9306053D0 (en) 1993-03-24 1993-05-12 Nycomed Pharma As Method and assay
WO2002037099A1 (fr) 2000-10-27 2002-05-10 International Reagents Corporation Procede de diagnostic de la nephropathie
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20070233391A1 (en) 2002-03-07 2007-10-04 Cambridge University Technical Service Limited (CUTS) Scd fingerprints
US20030198959A1 (en) * 2002-03-28 2003-10-23 Kurnit David M. Methods and compositions for analysis of urine samples in the diagnosis and treatment of kidney diseases
GB0215509D0 (en) * 2002-07-04 2002-08-14 Novartis Ag Marker genes
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
EP1743172A2 (en) 2004-04-16 2007-01-17 University of Massachusetts Detection and quantification of intracellular pathogens
US20060104902A1 (en) * 2004-08-17 2006-05-18 Garth Powis Method of preselection patients for anti-VEGF, anti-HIF-1 or anti-thioredoxin therapy
US7790463B2 (en) 2006-02-02 2010-09-07 Yale University Methods of determining whether a pregnant woman is at risk of developing preeclampsia
US7820159B2 (en) * 2006-10-31 2010-10-26 Instiute of Virology of the Slovak Academy of Sciences MN/CA IX and EGFR pathway inhibition
WO2008075173A2 (en) * 2006-12-15 2008-06-26 Ruprecht-Karls-Universität Heidelberg Methods for treating podocyte-related disorders
KR20100039284A (ko) 2007-05-21 2010-04-15 웨이크 포리스트 유니버시티 헬스 사이언시즈 소변으로부터의 전구 세포 및 이를 사용하는 방법
US20090068683A1 (en) 2007-06-11 2009-03-12 Mayo Foundation For Medical Education And Research Markers for preeclampsia
US20090104649A1 (en) 2007-06-11 2009-04-23 Garovic Vesna D Markers for preeclampsia
CN101970486A (zh) * 2007-10-25 2011-02-09 布里斯托尔大学 特异于血管内皮生长因子(vegf)的促血管发生同工型的抗体
WO2010065968A1 (en) 2008-12-05 2010-06-10 Myriad Genetics, Inc. Cancer detection markers
WO2010143423A1 (ja) 2009-06-10 2010-12-16 国立大学法人 新潟大学 糖尿病性腎症の検査方法
US20130034861A1 (en) 2009-12-21 2013-02-07 Mayo Foundation For Medical Education And Research Early marker of proteinuria in patients treated with an anti-vegf treatment
KR102428776B1 (ko) 2010-05-12 2022-08-04 인리젠 생물활성 신장 세포
EP2856164B1 (en) 2012-06-01 2018-07-11 Mayo Foundation For Medical Education And Research High-throughput early detection and point-of-care early detection of pregnant women susceptible to developing preeclampsia
WO2014055687A1 (en) 2012-10-05 2014-04-10 Hitachi Chemical Co., Ltd. Urine exosome mrnas and methods of using same to detect diabetic nephropathy
WO2015080838A1 (en) 2013-11-27 2015-06-04 Mayo Foundation For Medical Education And Research Detecting podocyte injury in diabetic nephropathy and glomerulonephritis

Also Published As

Publication number Publication date
US20160060333A1 (en) 2016-03-03
EP2517014B1 (en) 2014-11-19
AU2010339723B2 (en) 2014-11-06
EP2517014A2 (en) 2012-10-31
US10336822B2 (en) 2019-07-02
BR112012017767A2 (pt) 2019-09-24
US20130296397A1 (en) 2013-11-07
JP2013515268A (ja) 2013-05-02
WO2011084791A3 (en) 2011-11-24
CA2785273A1 (en) 2011-07-14
EP2517014A4 (en) 2013-07-17
AU2010339723A1 (en) 2012-08-09
US20180002416A1 (en) 2018-01-04
US20130034861A1 (en) 2013-02-07
JP5753541B2 (ja) 2015-07-22
US9765137B2 (en) 2017-09-19
US9213038B2 (en) 2015-12-15
WO2011084791A2 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
CY1120961T1 (el) Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος
AU2018256633A1 (en) Therapy for enteric infections
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
NZ584787A (en) Inhibition of angiogenesis with a Bv8 antagonist
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
BRPI1007321A2 (pt) métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo.
AR084373A1 (es) Composiciones y metodos para la eliminacion de biopeliculas
ES2572372T3 (es) Método de diagnóstico de enfermedades neurodegenerativas basado en la medición de los niveles o de la actividad de SIRT1
EA202190319A1 (ru) Композиции и способы детектирования биологического загрязнителя
BR112012029281A2 (pt) anticorpo trop-2 anti-humano tendo atividade anti-tumor in vivo
WO2010091049A3 (en) Diagnosis and treatment of cancer
BRPI0906549A2 (pt) Bandagens médicas com válvulas e kits contendo as mesmas.
EA200901550A1 (ru) Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений
UY32698A (es) Marcadores de riesgo para enfermedades cardiovasculares
BRPI1013705A2 (pt) compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
WO2010085542A3 (en) Biomarkers related to age-related macular degeneration (amd)
BR112012017768A2 (pt) implante interespinhal
BRPI0918386A2 (pt) métodos de avaliação de um paciente para incontinência urinária de esforço, sistema de avaliação de um paciente para incontinência urinária de esforço e dispositivo para avaliação de um paciente para incontinência urinária de esforço
BRPI1015014A2 (pt) composto, composição farmacêutica , e, método de tratamento de distúrbio(s) cognitivo(s) ou indicações com déficit(s) em cognição
WO2010124101A3 (en) Genetic markers associated with endometriosis and use thereof
ES2530743T3 (es) Método in vitro y kit para el pronóstico o predicción de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor TNFalfa
ES2530866T3 (es) Marcador temprano de proteinuria en pacientes tratados con un tratamiento anti-VEGF
BRPI1015216A2 (pt) método de tratar ou prevenir uma condição médica em um indivíduo.
CL2011002260A1 (es) Metodo o sistema para el seguimiento del tratamiento de un individuo que comprende determinar si una muestra de dicho individuo comprende un biomarcador.